IDYA ideayabio.com Net earnings per share growth forecast for next year

Corporate company logo of IDEAYA Corp (IDYA)

IDEAYA Biosciences (IDYA) is implementing green chemistry principles to minimize toxic waste during the development of targeted therapies. Business success depends on darovasertib trials and the extent of the cash runway. Revenue expectations are forming as interim phase data is published. The consensus earnings per share forecast reflects a fundamental valuation reassessment, while the value 7.70 captures this metric.

IDYA: IDEAYA Biosciences Inc Net earnings per one share growth forecast for next year 07/04/2022 - 11/13/2026

Financial and market metric breakdowns for ideayabio.com (IDYA)

- share price and consensus valuation forecast:
Stock Price IDEAYA Bio|IDYA - Analyst Consensus Forecast
- market capitalization data:
Market Value IDEAYA Biosciences|IDYA - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share IDEAYA Biosciences|IDYA - Book Value of Business|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio IDEAYA Biosciences|IDYA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital IDEAYA Biosciences, Inc.|IDYA - Company Cumulative Debt|Debts to Book Capitalization IDEAYA Biosciences|IDYA - Company Long-Term Indebtedness|Company Current Liabilities IDEAYA Biosciences|Quick Liquidity Indicator ideayabio.com
- earnings and valuation multiples information:
IDYA - Profit After Payment of Taxes|Projected Future Earnings IDEAYA Biosciences|IDYA - Company Value to Net Income|Forward P/E Multiple IDEAYA Biosciences|IDYA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization IDEAYA Biosciences|IDYA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) IDEAYA Biosciences|IDYA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ideayabio.com|IDYA - Earnings per share trend in current year|Expected earnings per share growth for next year IDEAYA Biosciences
- sales and revenue data:
IDYA - Company Total Revenue|Projected Sales Volume IDEAYA Bio|IDYA - Price-to-Revenue Coefficient|Forward P/S Multiple IDEAYA Biosciences
Fundamental company analysis:IDEAYA Bio, IDYA
Brand item of ideayabio.com

As a portfolio manager, I view this indicator as a leading marker for the revision of market earnings per share expectations. By analyzing the projected net profit growth rate for n+1 on GURU.Markets, an investor assesses the probability of darovasertib commercialization and the effectiveness of IDEAYA Biosciences (IDYA) alliances with pharma behemoths, where sharp shifts in the curve signal a change in the fundamental valuation of the precision oncology pipeline.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year ELVN (Enliven Therapeutics, Inc.)|Net earnings per one share growth forecast for next year ORIC Pharmaceuticals Inc|Relay Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Nurix Corp|TYRA (Tyra Biosciences, Inc.) - Expected earnings per share growth for next year|VSTM: Projected earnings per share increase next year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)